MarginsXMarginsX
Home › Markets › Health Care › ICLR

ICON plc (ICLR)

ICLR trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$191.40
-1.67% on the day
Market cap
$14.7B
Large cap
Revenue · 2025
$8.3B
+0.8% on 2024
Net income · 2025
$229.3M
2.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1060955/000162828026038487/0001628280-26-038487-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerICLR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Commercial Physical & Biological Resarch
CountryIreland
IPO year1998
SEC CIK0001060955
SEC industry codeServices-Commercial Physical & Biological Research

Financials · 2025

LineValue
Revenue$8.3B
Net income$229.3M
Operating income$442.8M
Net margin2.8%
Operating margin5.4%
Revenue growth+0.8%
Cash$647.3M
Total assets$16.3B
P/E (computed)63.9×
P/S (computed)1.8×

Warning signs

Cash runway
Cash-flow positive
$647.3M cash at December 31, 2025
Share count, 1 year
-5.2%
2024-12-31 to 2025-12-31 · -6.3% over 3 years
Going-concern doubt
No
20-F filed May 27, 2026
Insider net buying, 12 months
-$3.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-05-27
Cash and burn$647.3M cash; operating cash flow $259.1M a quarter.Report 2025-12-31
Shares outstanding76,567,325 (2025-12-31); 80,756,860 a year earlier; 81,723,555 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG, Dublin, IrelandPCAOB Form AP 2026-06-24
Late filings, 12 months1 NT noticeNT 20-F 2026-05-01
Insider trades, 12 monthsBought $0, sold $3.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$8.3B$229.3M$1.0B$647.3M$2.9B$8.3B20-F 2026-05-27
FY 2024
2024-12-31
$8.2B$739.1M$1.3B$538.8M$3.4B$8.2B20-F 2026-05-27
FY 2023
2023-12-31
$8.1B$554.2M$1.2B$378.1M$3.8B$8.1B20-F 2026-05-27
FY 2022
2022-12-31
$7.7B$505.3M$563.3M$288.8M$4.7B$7.7B20-F 2025-02-21
FY 2021
2021-12-31
$5.5B$153.2M$829.1M$752.2M$5.5B$5.5B20-F 2024-02-23
FY 2020
2020-12-31
$2.8B$332.3M$568.0M$840.3M$348.5M$2.8B20-F 2023-02-24
FY 2019
2019-12-31
$2.8B$374.0M$412.5M$520.3MNo debt tags$2.8B20-F 2022-03-01
FY 2018
2018-12-31
$2.6B$322.7M$268.6M$395.9MNo debt tags$2.6B20-F 2021-02-24

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-05-02
Latest annual report20-F2026-05-27
Latest quarterly / interim6-K2026-11-10

Source: SEC EDGAR submissions feed, 845 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.9%
1 month+18.4%
3 months+16.2%
Year to date+6.8%
1 year+19.1%
From 52-week high-9.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Commercial Physical & Biological Resarch

TickerCompanyPriceDayMarket cap
CRLCharles River Laboratories International Inc.$335.52-0.72%$16.1B
MEDPMedpace Holdings Inc.$648.20-0.88%$18.1B
INCYIncyte Corp.$120.27-0.58%$24.5B
IQVIQVIA Holdings Inc.$264.73-0.15%$43.6B
ABSIAbsci Corporation$7.47-11.54%$1.3B
OABIOmniAb Inc.$4.89-0.41%$713.3M
NRCNRC Health$26.33-0.87%$558.8M
MXCTMaxCyte Inc.$1.18-0.84%$121.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier